Medicalgorithmics S.A. — Capital/Financing Update 2026

Jan 20, 2026

Report Content Receipt by the Company of an offer from BioFund Capital Management LLCfor a change to the loan agreement terms beneficial to the Company(reduction of financing costs) and information regarding negotiations onthe conversion of liabilities under loan agreements into the Company'sshares and submission to a lock-up

Current Report No.: 5/2026

Date: 20 January 2026

Legal basis: Article 17(1) MAR - inside information.

The Management Board of Medicalgorithmics S.A., with its registeredoffice in Warsaw (the "Issuer" or the "Company"), hereby announces thaton 20 January 2026 it received from the Company's shareholder, BioFundCapital Management LLC ("BioFund"), an offer to amend the terms(reduction of financing costs) of the loan agreement dated 29 November2024, as amended by an annex dated 15 April 2025 (jointly, the "LoanAgreement"), in the following scope:

1. repeal of BioFund's right to a commission amounting to 3% of revenuesfrom new customers pursuant to Article 7 of the Loan Agreement;

2. reduction of the loan interest rate specified in Section 4.1 of theLoan Agreement from 18.5% to 14% per annum;

3. extension of the maturity date of the loan granted under the LoanAgreement by 6 months, i.e. the maturity date of the first loanrepayment instalment to be postponed from 31 October 2026 to 30 April2027, with the maturity dates of the remaining instalments extendedaccordingly.

The document received by the Company also indicates that BioFund isprepared to conduct appropriate negotiations aimed at converting theloan granted under the Loan Agreement (principal and accrued interest)into the Company's shares, taking into account an independent fairnessopinion, and at BioFund's submission to an obligation not to dispose ofshares (lock-up) with respect to all shares held by BioFund.

In the Management Board's opinion, the actions referred to in thedocument received by the Company will be beneficial to the Company, asthey will result in a reduction of financing costs and an improvement incash flows.

The recapitalisation of the Company and the allocation of the fundsobtained to the repayment of the majority of indebtedness will, in theManagement Board's assessment, strengthen Medicalgorithmics' balancesheet position, increase financial stability and improve flexibility inliquidity management.

In connection with the above, the Company intends to conduct thenegotiations referred to above and to undertake actions aimed atachieving the objective described above.